JP5221383B2 - ピリド(3,2,1−ij)−ベンズオキサジアジン型の化合物を含む、抗感染剤溶液 - Google Patents
ピリド(3,2,1−ij)−ベンズオキサジアジン型の化合物を含む、抗感染剤溶液 Download PDFInfo
- Publication number
- JP5221383B2 JP5221383B2 JP2008551835A JP2008551835A JP5221383B2 JP 5221383 B2 JP5221383 B2 JP 5221383B2 JP 2008551835 A JP2008551835 A JP 2008551835A JP 2008551835 A JP2008551835 A JP 2008551835A JP 5221383 B2 JP5221383 B2 JP 5221383B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- acid
- solution according
- solubilizer
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002924 anti-infective effect Effects 0.000 title claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 30
- -1 1-imidazolyl Chemical group 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims abstract description 8
- 235000012209 glucono delta-lactone Nutrition 0.000 claims abstract description 8
- 229960003681 gluconolactone Drugs 0.000 claims abstract description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 3
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000003381 stabilizer Substances 0.000 claims description 18
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 6
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 5
- 239000000174 gluconic acid Substances 0.000 claims description 5
- 235000012208 gluconic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 15
- 239000007924 injection Substances 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 13
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 abstract description 9
- 229960002531 marbofloxacin Drugs 0.000 abstract description 8
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 abstract description 4
- 230000003902 lesion Effects 0.000 abstract description 4
- IIGPLHDJKDEXJA-UHFFFAOYSA-N 2h-1,2,3-benzoxadiazine Chemical class C1=CC=C2C=NNOC2=C1 IIGPLHDJKDEXJA-UHFFFAOYSA-N 0.000 abstract description 3
- 241000282887 Suidae Species 0.000 abstract description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000012873 virucide Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 2
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical class 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940099563 lactobionic acid Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- JHGGOTFKWARTGB-UHFFFAOYSA-N CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O Chemical compound CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O JHGGOTFKWARTGB-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004385 danofloxacin Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Xは、水素若しくはハロゲン原子或いはヒドロキシ官能基、そして特にフッ素原子、を表し、
R1は、以下の:
4位においてメチル、アセチル又は4−アミノベンジル基で置換されてよい、1−ピペラジニルラジカル;
モルホリノラジカル;
3位において塩素原子又はアミノ、アミノメチル、(メチルアミノ)メチル、(エチルアミノ)メチル若しくはメトキシ基で置換された、1−ピロリジニルラジカル;
4位においてメチル基で置換されることができる1−イミダゾリルラジカル;或いは
4位においてヒドロキシ又はメトキシ基で置換された1−ピペリジルラジカルを表し、
R2は、1〜10個の炭素原子を含む、直鎖、分岐鎖又は環状のアルキルラジカル、特にメチル基を表す。}
に適合する化合物及びその医薬として許容可能な塩を意味する。
−鉱酸、特に、塩酸、臭化水素酸、硫酸、リン酸及び硝酸、並びに
−炭酸、スルホン酸及びホスホン酸などの有機酸、特に、葉酸、酢酸、プロピオン酸、コハク酸、グリコール酸、乳酸又はポリ乳酸、リンゴ酸、酒石酸、クエン酸、アスコルビン酸、マレイン酸、ヒドロキシマレイン酸、フェニル酢酸、安息香酸、4−アミノ安息香酸、アントラニル酸、4−ヒドロキシ安息香酸、サリチル酸、アミノサリチル酸、ニコチン酸、メタンスルホン酸、エタンスルホン酸、ヒドロキシエタンスルホン酸、ベンゼンスルホン酸及びp−トルエンスルホン酸;グルコン酸、グルクロン酸、ガラクツロン酸、イソフタル酸及びラクトビオン酸などのポリカルボン酸;アスパラギン酸及びグルタミン酸、メチオニン、トリプトファン、リジン及びアルギニンなどのアミノ酸;そのエステル、中でもグルコノラクトンが挙げられることができ、並びにその塩、そして、
その混合物
が挙げられることができる。
R3、R4、R5、R6、R7、R8及びR9は、独立して、水素、ハロゲン原子、置換されてよいアルコール、エーテル又はアミン官能基、置換されてよいチオエーテル、エステル又はアミン官能基、或いはアルキル、アリール、アラルキル、アルカリールラジカルをあらわす。}
に適合する化合物を意味する。
溶媒、例えば、腸管外に使用可能な非水性溶媒、すなわち、水と非混和性の溶媒、例えば、植物油又はオレイン酸エチル、或いは水と混和性の溶媒、特にエタノールなどのアルコール;N,Nジメチルアセトアミドなどのアミド;ポリグルコセイテッド(polyglucosated)グリセライドなどのポリオールエステル;ジメチル−1,3−ジオキソラン−4−メタノール、ジエチレングリコールモノエチリックエーテル、グリセロールフォーマル、ポリエチレングリコール、特にPEG300及びPEG400などのエーテル;グリセロール又はプロピレングリコールなどのポリオール;ジメチルスルホキシド;2−ピロリドン;或いはこれらの混合物、
界面活性剤、例えば、非イオン性、アニオン性、カチオン性の界面活性剤、又は界面活性剤の混合物、特に非イオン性界面活性剤;
キレート剤、例えば、EDTA;
保存剤、特に抗酸化剤;或いは
抗菌剤、並びにこれらの混合物、から成る群から選ばれる添加剤を含むこともできる。
−鉱酸、特に塩酸、臭化水素酸、硫酸、リン酸及び硝酸、並びに
−有機酸、たとえば、カルボン酸、スルホン酸及びホスホン酸;特に、葉酸、酢酸、プロピオン酸、コハク酸、グリコール酸、乳酸またはポリ乳酸、リンゴ酸、酒石酸、クエン酸、アスコルビン酸、マレイン酸、ヒドロキシマレイン酸、フェニル酢酸、安息香酸、4−アミノ安息香酸、アンスラニリン酸、4−ヒドロキシ安息香酸、サリチル酸、アミノサリチル酸、ニコチン酸、メタンスルホン酸、エタンスルホン酸、ヒドロキシエタンスルホン酸、ベンゼンスルホン酸、及びp−トルエンスルホン酸;ポリカルボン酸、たとえば、グルコン酸、グルクロン酸、ガラクツロン酸、イソフタル酸及びラクトビオン酸;アミノ酸、たとえば、アスパラギン酸及びグルタミン酸、メチオニン、トリプトファン、リジン及びアルギニン;そのエステル、中でもグルコノラクトン、並びにその塩、そして
−それらの混合物
から選ばれる少なくとも1つの化合物の使用に関する。
以下の表1に記載される溶液を調製した。
以下のバッチを調製した。
Claims (12)
- 抗感染剤溶液であって、以下の:
(i)前記溶液の全体積に対して10重量%〜30重量%の、以下の式(I):
Xは、水素若しくはハロゲン原子またはヒドロキシ官能基を表し、
R1は、4位においてメチル、アセチルまたは4−アミノベンジル基で置換されてよい、1−ピペラジニルラジカル;モルホリノラジカル;3位において塩素原子又はアミノ、アミノメチル、(メチルアミノ)メチル、(エチルアミノ)メチル若しくはメトキシ基で置換された1−ピロリジニルラジカル;4位においてメチル基で置換されることができる1−イミダゾリルラジカル;或いは4位においてヒドロキシまたはメトキシ基で置換された1−ピペリジルラジカルを表し、
R2は、1〜10個の炭素原子を含む、直鎖、分岐鎖または環状のアルキルラジカルを表す。}
に適合する、少なくとも1つの化合物又は少なくとも1つの医薬として許容可能なその塩;
(ii)安定化剤としてのベンジルアルコール;及び
(iii)有機酸及びそのエステルから成る群から選ばれる少なくとも1つの溶解剤、
を医薬として許容可能な担体中に含む、前記溶液。 - 前記化合物が式(I)に適合し、式中、R1が4位においてメチル基で置換された1−ピペラジニルラジカルを表し、R2がメチル基を表し、そしてXがフッ素原子を表す、請求項1に記載の溶液。
- 前記溶液の全体積に対して11重量%〜20重量%の割合の式(I)の化合物を含む、請求項1又は2に記載の溶液。
- 前記溶解剤が、乳酸、グルコン酸及びグルコノラクトンから成る群から選ばれる、請求項1〜3のいずれか1項に記載の溶液。
- 前記溶液の全体積に対して4重量%〜58重量%の割合の溶解剤を含む、請求項1〜4のいずれか1項に記載の溶液。
- 前記溶解剤と式(I)の化合物のモル比が、0.9〜4である、請求項1〜5のいずれか1項に記載の溶液。
- 前記溶解剤が、前記溶液のpHが2〜7となる割合で存在する、請求項1〜6のいずれか1項に記載の溶液。
- 前記溶液の全体積に対して0.2重量%〜20重量%の割合の安定化剤を含む、請求項1〜7のいずれか1項に記載の溶液。
- モル比が0.02〜7である、前記安定化剤と式(I)の化合物を含む、請求項1〜8のいずれか1項に記載の溶液。
- 2〜7のpHを有する、請求項1〜9のいずれか1項に記載の溶液。
- 抗感染薬としての使用のための請求項1〜10のいずれか1項に記載の溶液。
- 動物における感染の治療または予防を目的とする医薬を得るための、請求項1〜11のいずれか1項に記載の溶液の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0650246 | 2006-01-24 | ||
FR0650246A FR2896416B1 (fr) | 2006-01-24 | 2006-01-24 | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
PCT/FR2007/050682 WO2007085760A2 (fr) | 2006-01-24 | 2007-01-24 | Solution anti-infectieuse comprenant un compose de type pyrido(3,2,1-ij)-benzoxadiazine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009523840A JP2009523840A (ja) | 2009-06-25 |
JP5221383B2 true JP5221383B2 (ja) | 2013-06-26 |
Family
ID=36748355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551835A Active JP5221383B2 (ja) | 2006-01-24 | 2007-01-24 | ピリド(3,2,1−ij)−ベンズオキサジアジン型の化合物を含む、抗感染剤溶液 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8796265B2 (ja) |
EP (2) | EP1976561B1 (ja) |
JP (1) | JP5221383B2 (ja) |
CN (1) | CN101405032B (ja) |
AT (1) | ATE520418T1 (ja) |
AU (1) | AU2007209245B2 (ja) |
BR (1) | BRPI0706956B1 (ja) |
CA (1) | CA2637941C (ja) |
CY (1) | CY1112481T1 (ja) |
DK (1) | DK1976561T3 (ja) |
EA (1) | EA016154B1 (ja) |
ES (2) | ES2813856T3 (ja) |
FR (1) | FR2896416B1 (ja) |
HK (1) | HK1128883A1 (ja) |
HU (1) | HUE050643T2 (ja) |
IL (1) | IL192935A (ja) |
MX (1) | MX2008009470A (ja) |
NO (1) | NO20083422L (ja) |
NZ (1) | NZ570332A (ja) |
PL (2) | PL2438929T3 (ja) |
PT (2) | PT1976561E (ja) |
SI (2) | SI2438929T1 (ja) |
UA (1) | UA94086C2 (ja) |
WO (1) | WO2007085760A2 (ja) |
ZA (1) | ZA200806369B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107107001B (zh) * | 2014-12-31 | 2020-11-03 | 通用电气医疗集团生物科学公司 | 用于一次性生物反应器的轴安装式流体传递组件 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
EP2332916A3 (en) | 2009-11-19 | 2011-08-03 | Krka Tovarna Zdravil, D.D., Novo Mesto | A process for a preparation of marbofloxacin and intermediate thereof |
CN103271875A (zh) * | 2013-07-01 | 2013-09-04 | 浙江华尔成生物药业股份有限公司 | 一种注射用麻保沙星冻干粉及其制备方法与应用 |
US10440147B2 (en) | 2015-11-24 | 2019-10-08 | William Edward Woodcock, IV | Quality-of-service management for domain name service |
US20170239250A1 (en) | 2016-02-19 | 2017-08-24 | Eagle Pharmaceuticals, Inc. | Pemetrexed formulations |
CN107445977B (zh) * | 2017-07-13 | 2019-08-09 | 江西傲新生物科技有限公司 | 一种水溶性马波沙星及其制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3537761A1 (de) * | 1985-10-24 | 1987-04-30 | Bayer Ag | Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure |
DE3788177D1 (de) * | 1986-09-12 | 1993-12-23 | Hoffmann La Roche | Pyrido [3,2,1-ij]-1,3,4-benzoxadiazinderivate, Verfahren zu deren Herstellung, entsprechende pharmazeutische Präparate und im Verfahren verwendbare Zwischenprodukte. |
DE19500784A1 (de) * | 1995-01-13 | 1996-07-18 | Bayer Ag | Enrofloxacin-Injektions- oder Infusionslösungen |
DE19519822A1 (de) * | 1995-05-31 | 1996-12-05 | Bayer Ag | Neue antibakterielle Mittel |
PL186795B1 (pl) | 1995-12-21 | 2004-02-27 | Pfizer | Preparat farmaceutyczny zawierający danofloksacynę |
GB9600894D0 (en) * | 1996-01-17 | 1996-03-20 | Pfizer | Novel compound |
GB9600886D0 (en) * | 1996-01-17 | 1996-03-20 | Pfizer | Novel compound |
GB9601356D0 (en) * | 1996-01-24 | 1996-03-27 | Pfizer | Novel compound |
DE19633480A1 (de) * | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
DE10337191A1 (de) * | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
CA2546195A1 (en) * | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | The use of anti biotics as vaccine adjuvants |
-
2006
- 2006-01-24 FR FR0650246A patent/FR2896416B1/fr active Active
-
2007
- 2007-01-24 DK DK07731510.9T patent/DK1976561T3/da active
- 2007-01-24 US US12/161,827 patent/US8796265B2/en active Active
- 2007-01-24 BR BRPI0706956A patent/BRPI0706956B1/pt active IP Right Grant
- 2007-01-24 WO PCT/FR2007/050682 patent/WO2007085760A2/fr active Application Filing
- 2007-01-24 MX MX2008009470A patent/MX2008009470A/es active IP Right Grant
- 2007-01-24 AT AT07731510T patent/ATE520418T1/de active
- 2007-01-24 PT PT07731510T patent/PT1976561E/pt unknown
- 2007-01-24 NZ NZ570332A patent/NZ570332A/en not_active IP Right Cessation
- 2007-01-24 CA CA2637941A patent/CA2637941C/fr active Active
- 2007-01-24 ES ES11177669T patent/ES2813856T3/es active Active
- 2007-01-24 HU HUE11177669A patent/HUE050643T2/hu unknown
- 2007-01-24 CN CN2007800033484A patent/CN101405032B/zh not_active Expired - Fee Related
- 2007-01-24 EA EA200801733A patent/EA016154B1/ru not_active IP Right Cessation
- 2007-01-24 SI SI200732159T patent/SI2438929T1/sl unknown
- 2007-01-24 EP EP07731510A patent/EP1976561B1/fr active Active
- 2007-01-24 PL PL11177669T patent/PL2438929T3/pl unknown
- 2007-01-24 UA UAA200810611A patent/UA94086C2/ru unknown
- 2007-01-24 AU AU2007209245A patent/AU2007209245B2/en not_active Ceased
- 2007-01-24 PT PT111776696T patent/PT2438929T/pt unknown
- 2007-01-24 ES ES07731510T patent/ES2371941T3/es active Active
- 2007-01-24 JP JP2008551835A patent/JP5221383B2/ja active Active
- 2007-01-24 PL PL07731510T patent/PL1976561T3/pl unknown
- 2007-01-24 EP EP11177669.6A patent/EP2438929B1/fr active Active
- 2007-01-24 SI SI200730767T patent/SI1976561T1/sl unknown
-
2008
- 2008-07-21 IL IL192935A patent/IL192935A/en active IP Right Grant
- 2008-07-22 ZA ZA200806369A patent/ZA200806369B/xx unknown
- 2008-08-05 NO NO20083422A patent/NO20083422L/no not_active Application Discontinuation
-
2009
- 2009-09-23 HK HK09108668.5A patent/HK1128883A1/xx not_active IP Right Cessation
-
2011
- 2011-11-16 CY CY20111101104T patent/CY1112481T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107107001B (zh) * | 2014-12-31 | 2020-11-03 | 通用电气医疗集团生物科学公司 | 用于一次性生物反应器的轴安装式流体传递组件 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5221383B2 (ja) | ピリド(3,2,1−ij)−ベンズオキサジアジン型の化合物を含む、抗感染剤溶液 | |
AP1235A (en) | NMDA receptor agonist pharmaceutical compositions. | |
ES2560102T3 (es) | Estabilización de vitamina B12 | |
JP5584418B2 (ja) | フルオロキノロン類を含有する医薬 | |
JP2008543832A (ja) | フルフェナジンおよびその誘導体を含むフェノチアジンのための新しい調合物 | |
CA2644981C (en) | Pharmaceutical formulation comprising fluoroquinolones | |
TWI718158B (zh) | 藥學組成物 | |
WO2016195014A1 (ja) | 水性液剤 | |
CN112843042A (zh) | 长效酮洛芬组合物 | |
TWI228048B (en) | New formulation | |
PT2125782E (pt) | Derivados ciclo-hexilamida de ácidos arilcarboxílicos | |
JP2002532437A (ja) | トリフェニルエチレン型抗エストロゲンの水溶性組成物 | |
KR100748252B1 (ko) | 플로르페니콜 및 타이로신 함유 주사용 조성물 | |
WO2007016153A2 (en) | Tilmicosin formulation | |
EA022765B1 (ru) | Фармацевтическая композиция | |
CN114533661A (zh) | 一种稳定的马波沙星注射溶液 | |
JP6031216B1 (ja) | 水性液剤 | |
JPS6219569A (ja) | キノロンカルボン酸類のエンボネート類 | |
CN109431981A (zh) | 一种恩诺沙星注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130307 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160315 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5221383 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |